Transcode Therapeutics Inc (NASDAQ: RNAZ) is a clinical-stage biopharmaceutical company developing RNA-based therapeutic candidates. The company generates no product revenue and funds operations through grants and equity financing rather than commercial sales. As of April 3, 2026, RNAZ had 12 employees working across six states. The company recorded total operating expenses of $27.98 million in FY2025, including $13.42 million in research and development costs and $14.56 million in general and administrative expenses (which included $8.79 million in acquisition-related transaction costs). Grant income was $1.28 million in FY2025 versus $0.52 million in FY2024. The company carries convertible notes issued to Yorkville and has up to $95 million in contingent milestone payment obligations tied to development and regulatory milestones for its acquired lead candidate. RNAZ effected a 28-for-1 reverse stock split on May 15, 2025, and received a Nasdaq bid price compliance notice resolved by June 2, 2025.

Revenue model

No product revenue as of the FY2025 10-K filing. Funding comes from government or institutional grants ($1.28 million in FY2025) and equity and convertible debt financing. Future revenue is contingent on clinical development milestones and eventual commercialization of therapeutic candidates.

Products and services

Lead therapeutic candidate TTX-MC138, an RNA-based compound evaluated in preclinical and early clinical settings, including imaging studies using positron emission tomography for quantitation of delivery to metastatic lesions. The company also holds rights to an acquired seller lead candidate subject to up to $95 million in milestone payments to DEFJ upon Phase 3, BLA submission, and FDA approval events within ten years of the acquisition.

Customers and end markets

No commercial customers as of the FY2025 filing. End market is oncology and RNA-targeted therapeutics. Development activities include clinical trials subject to FDA regulatory oversight and potential EU clinical trial activities subject to GDPR.

Value-chain role

Pre-commercial drug developer. Relies on Michigan State University (MSU) for certain development activities and third-party contract research organizations (CROs) for clinical and preclinical work. Holds licensed intellectual property from a licensor with milestone and change-of-control payment obligations.

Geographic exposure

Primary operations in the United States, with employees across six states as of April 3, 2026. Potential EU clinical trial activities subject to GDPR compliance. No disclosed international revenue.

Source: SEC 10-K, filed 2026-04-15

Industry: Pharmaceutical Preparations Peers: American CryoStem Corp NeuBase Therapeutics, Inc. BIOCEPT INC Ernexa Therapeutics Inc Calithera Biosciences, Inc. Soleno Therapeutics Inc Skye Bioscience Inc MetaVia Inc